Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib

Digestive Diseases

Volumn 32, Issue 6, 2014, Pages 705-710

  Arizumi, Tadaaki ^a   Ueshima, Kazuomi ^a   Chishina, Hirokazu ^a   Kono, Masashi ^a   Takita, Mashiro ^a   Kitai, Satoshi ^a   Inoue, Tatsuo ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Minami, Yasunori ^a   Sakurai, Toshiharu ^a   Nishida, Naoshi ^a   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; mRECIST; Sorafenib; Stable disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; DECARBOXYPROTHROMBIN; HEPATITIS ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C VIRUS ANTIBODY; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; CONFERENCE PAPER; DIARRHEA; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; INTERSTITIAL PNEUMONIA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; TUMOR VOLUME; ADULT; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; JAPAN; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84910625296     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000368006     Document Type: Conference Paper

References (24)

1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
3. Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14.
4. Belghiti J, Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer 2012;1:71-82.
5. Shindoh J, Kaseb A, Vauthey JN: Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer 2013;2:47-54.
6. Lee Cheah Y, Chow P K H: Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer 2012;1:183-189.
7. Chan SC: Liver transplantation for hepatocellular carcinoma. Liver Cancer 2013;2:338-344.
8. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-524.
9. Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM: Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008;23:467-473.
10. Lin SM: Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer 2013;2:73-83.
11. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012;1:41-50.
12. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1:62-70.
13. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588-595.
14. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M: Combination therapy of intraarterial 5-fluorouracil and systemic interferonalpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006;106:1990-1997.
15. Lin S, Hoffmann K, Schemmer P: Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-158.
16. Peck-Radosavljevic M: Drug therapy for advanced-stage liver cancer. Liver Cancer 2014;3:125-131.
17. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX: NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350-391.
18. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
19. Raoul JL, Gilabert M, Piana G: How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 2014;3:119-124.
20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, De Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
21. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
22. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
23. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T: Des-gamma-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011;29:321-325.
24. Nakazawa T, Hidaka H, Shibuya A, Koizumi W: Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. Case Rep Oncol 2010;3:298-303.